Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany

Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany

Background The fully human monoclonal antibody guselkumab is an effective treatment option for patients with moderate to severe psoriasis. Objective The objective of this study was to examine the cost per responder of guselkumab compared with other targeted therapies for the treatment of moderate to...

Full description

Bibliographic Details
Main Authors:	Matthias Augustin, Daniel Wirth, Jörg Mahlich, Alicia N. Pepper, Cheryl Druchok
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-02-01
Series:	Journal of Dermatological Treatment
Subjects:	guselkumab psoriasis biologic cost per responder
Online Access:	http://dx.doi.org/10.1080/09546634.2020.1793891

Similar Items

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
by: Ricardo Ruiz-Villaverde, et al.
Published: (2022-09-01)

Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis
by: Amanda Teeple, et al.
Published: (2022-01-01)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient: a case report
by: Nicoletta Bernardini, et al.
Published: (2022-07-01)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021-01-01)

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
by: Andrew Blauvelt, et al.
Published: (2022-05-01)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
by: Marloes E. van Muijen, et al.
Published: (2022-08-01)

Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
by: Paolo Gisondi, et al.
Published: (2021-09-01)

Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2
by: Luis Puig, et al.
Published: (2021-07-01)

Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy
by: Giuseppe Pompilio, et al.
Published: (2022-11-01)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
by: Yang EJ, et al.
Published: (2019-06-01)

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
by: Jianfeng Zheng, et al.
Published: (2023-12-01)

Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade
by: V. V. Chikin
Published: (2020-01-01)

Based on Gene Expression Analysis: Low-Density Neutrophil Expression Is a Characteristic of the Fast Responders Treated With Guselkumab for Psoriasis
by: Jiajing Lu, et al.
Published: (2022-05-01)

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
by: Marco Galluzzo, et al.
Published: (2020-07-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab
by: Kristian Reich, et al.
Published: (2020-08-01)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022-03-01)

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors
by: Nicole L. Bolick, et al.
Published: (2020-12-01)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-03-01)

Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024-12-01)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
by: Ana-Maria Orbai, et al.
Published: (2023-09-01)

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024-02-01)

Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study
by: N. Li, et al.
Published: (2022-01-01)

Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies
by: Hongyi Fu, et al.
Published: (2022-11-01)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-09-01)

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
by: Matteo Megna, et al.
Published: (2022-02-01)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
by: Erin Bartholomew, et al.
Published: (2023-09-01)

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
by: Byung Soo Kim, et al.
Published: (2023-09-01)

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
by: Christopher E. M. Griffiths, et al.
Published: (2022-02-01)

Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
by: Chan Y, et al.
Published: (2021-06-01)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
by: Ahmed Bagit, BSc, et al.
Published: (2023-09-01)

Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
by: Matteo Megna, et al.
Published: (2022-07-01)

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan
by: Shinichi Imafuku, et al.
Published: (2018-01-01)

The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
by: Nyholm N, et al.
Published: (2023-07-01)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
by: Seung-Won Jung, et al.
Published: (2022-05-01)

Axonal sensorimotor polyneuropathy after starting guselkumab
by: Issam Hamadah, et al.
Published: (2022-05-01)

Current advances in biological therapy of psoriasis: efficacy of guselkumab in real clinical practice
by: O. V. Zhukova, et al.
Published: (2022-03-01)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
by: Yuliya Lytvyn, PhD, et al.
Published: (2021-09-01)

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry
by: Jan Hugo, et al.
Published: (2023-02-01)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
by: Li Y, et al.
Published: (2022-10-01)